Dry Pharmaceutical Compositions for Topical Delivery of Oral Medications, Nasal Delivery and to Treat Ear Disorders

ABSTRACT

In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent.

CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application is a continuation of U.S. patent applicationSer. No. 14/797,860, filed Jul. 13, 2015, which is a continuation ofU.S. patent application Ser. No. 13/920,903, filed Jun. 18, 2013, nowU.S. Pat. No. 9,078,853, the entireties of which are incorporated hereinby reference.

FIELD OF THE INVENTION

The present application relates to compounded therapies. In particular,the present application relates to compositions for compounded therapyand methods of compounding medications.

BACKGROUND

The need for effective therapeutic treatment of patients has resulted inthe development of a variety of pharmaceutical composition deliverytechniques. Administration of a drug or drug combination in form of asolution or a suspension is often desirable. Degradation of activeagents can often occur in solutions or suspensions. As a result, manypharmaceutical formulations are restricted in the manner of theirdelivery, which may make them unsuitable for young children and otherpatients. Some solution or suspension formulations must be administeredwithin minutes after opening the formulation's container, and any unusedportion must be discarded after this time. Other formulations must beadministered with a carrier, for example a small selection of softfoods. Such restrictions can lead to reduced patient compliance as wellas wasted medication.

In other cases, although a particular drug may be chemically stable inwater, liquid formulations such as aqueous solutions and suspensions fororal administration are not used because of the unpalatatability of theparticular drug. Unpalatable drugs which are carried in aqueous mediaare tasted almost immediately upon ingestion and produce an unpleasanttaste or after-taste. For example, the antibiotics clarithromycin anderythromycin are valuable therapeutic agents for treating infections andare somewhat unpalatable.

Additional problems resulting in poor shelf life which can occur inliquid formulations include particle agglomeration, stratification, andcaking upon standing.

There is thus a need in the pharmaceutical formulation arts for stabledrug formulations which can be administered in the form of an aqueoussolution or suspension.

SUMMARY

In one embodiment, the invention provides a dry formulation comprisingone or more of the following actives in combination withpharmaceutically acceptable excipients or additives: a) at least oneantibiotic; b) at least one anti-inflammatory steroid; and c) at leastone antifungal agent. Any or all of the actives can be included. The dryformulation can be formulated in any suitable form, such as a capsule.Pharmaceutically acceptable excipients or additives may be included andcomprise at least one solvent, at least one emollient, at least onehumectant, at least one preservative, and at least one emulsifier; andoptionally including an acid, base, or buffering agent to adjust the pH;and include. In some embodiments, the pharmaceutically acceptableexcipients or additives include a base for use in pharmaceuticalcompounding and manufacturing of topical preparations.

In some embodiments, the dry formulation does not contain anantihistamine.

In another embodiment, the dry formulation comprises one or more of thefollowing actives in combination with pharmaceutically acceptableexcipients or additives: a) at least one leukotriene receptorantagonist; b) at least one anti-inflammatory steroid; and c) at leastone non-sedative antihistamine.

In some embodiments, the dry formulation is stable for 180 days.

Specific combinations of active ingredients include 5% azithromycin,1.5% fluticasone, and 1.5% fluconazole; 8% sulfamethoxazole, 5%trimethoprim, 1.5% fluticasone, and 1.5% fluconazole; 12.8% levofloxacinhemihydrate, 1.5% fluticasone, and 1.5% fluconazole; 1.5% fluticasoneand 1.5% fluconazole; 1.5% fluticasone.

Other specific combinations of active ingredients include 12.8%levofloxacin hemihydrate, 10% mupirocin, 1.5% fluticasone, and 5%itraconazole; 12.8% levofloxacin hemihydrate, 1.5% fluticasone, and 5%itraconazole; 12.8% levofloxacin hemihydrate, 1.5% fluticasone, and 1%amphotericin B; 16% tobramycin, 1.5% fluticasone, and 5% itraconazole;16% tobramycin, 1.5% fluticasone, and 1% amphotericin B; 10% mupirocin,1.5% fluticasone, and 5% itraconazole; 10% mupirocin, 1.5% fluticasone,and 1% amphotericin B; 5.15% vancomycin hydrochloride, 1.5% fluticasone,and 5% itraconazole; 5.15% vancomycin hydrochloride, 1.5% fluticasone,and 1% amphotericin B; 16% tobramycin, 20% mupirocin; 1.5% fluticasoneand 1% amphotericin B; 1.5% fluticasone and 5% itraconazole.

Other specific combinations of active ingredients include 0.3%montelukast, 1.5% fluticasone, 0.2% levocetirizine dihydrochloride;5.15% vancomycin hydrochloride, 20% mupirocin.

In other embodiments, methods of preparing administrable formulationsfrom the dry formulation are provided. In one embodiment, the inventionprovides methods of preparing an orally administrable formulationcomprising forming the dry formulations into an oral rinse or an oralsolution. The oral formulations so prepared are also within the scope ofthe invention.

In another embodiment, the invention provides methods of preparing anintranasally administrable formulation comprising forming the dryformulations into a nasal solution or suspension with a diluent suitablefor intranasal delivery of active ingredients. The formulations soprepared are also within the scope of the invention.

In another embodiment, the invention provides methods of preparing aformulation for aural administration comprising forming the dryformulations into a solution or suspension with a diluent suitable forotic delivery of active ingredients. The formulations so prepared arealso included in the scope of the invention.

The oral rinse may include diphenhydramine, aluminium hydroxide,magnesium hydroxide, simethicone, an antiviral agent, such as acyclovir,a local anesthetic such as lidocaine, and the orally administrableformulations obtained by the methods.

Other methods include methods for treating inflammatory, ulcerative andpainful conditions of mucosal surfaces of the upper alimentary canal ofa mammal comprising administering the orally administrable formulationto a mammal, such as a human. The orally administrable formulation mayan oral rinse in which the method comprises (1) swishing the oral rinseformulation; and (2) expectorating the oral rinse formulation. In otherembodiments, the orally administrable formulation is an oral solutionand the method comprises (1) swishing the oral solution; and (2)swallowing the oral solution.

Inflammatory, ulcerative and painful conditions include mucositis,aphthous stomatitis, oral lichen planus, eosinophilic esophogitis, anulcer, erythema migrans, a condition resulting from gingivitis or atooth extraction, antineoplastic therapy, such as radiation therapy orchemotherapy, or in connection with a bacterial, viral, or fungalinfection such as candidias and herpes labialis.

The intranasal formulation may be administered by methods such asinhalation, spraying, liquid stream lavage, nebulizing, or nasalirrigation. The administering may be to the sinus cavity or the lungs,for example. The formulation can be administered, for example, two orthree times a day.

Also provided are other methods for treating inflammatory, ulcerativeand painful conditions of the respiratory tract, respiratory airways orlungs of a mammal, such as a human, comprising administering to amammal, such as a human, the intranasally administrable formulations.Such conditions include those caused by a bacterial, viral, or fungalinfection, such as a pseudomonas infection or a MRSA infection. Thecondition can also include an upper respiratory tract infection lowerrespiratory tract infection, bronchiolitis, pneumonia, dyspnea, cough,(recurrent) wheezing and asthma.

Also provided are methods for treating inflammatory, ulcerative andpainful conditions of the ear of a mammal, such a human, comprisingadministering to said mammal the formulations for aural administration.The formulation can be administered by instillation of the solution orsuspension into the ear canal. The formulations can be administered, forexample, up to three times a day.

The conditions include otitis externa, otitis media, otorrhea, acutemastoiditis, otosclerosis, otic pain, otic bleeding, otic inflammation,Lermoyez's syndrome, Meniere's disease, vestibular neuronitis, benignparoxysmal positional vertigo, herpes zoster oticus, Ramsay Hunt'ssyndrome, viral neuronitis, ganglionitis, geniculate herpes,labyrinthitis, purulent labyrinthitis, perilymph fistulas, presbycusis,drug-induced ototoxicity, acoustic neuromas, aerotitis media, infectiousmyringitis, bullous myringitis, squamous cell carcinoma, basal cellcarcinoma, pre-cancerous otic conditions, nonchromaffin paragangliomas,chemodectomas, glomus jugulare tumors, glomus tympanicum tumors,perichondritis, aural eczematoid dermatitis, malignant external otitis,subperichondrial hematoma, ceruminomas, impacted cerumen, sebaceouscysts, osteomas, keloids, otalgia, tinnitus, vertigo, tympanic membraneinfection, tympanitis, otic furuncles, petrositis, conductive andsensorineural hearing loss, epidural abscess, lateral sinus thrombosis,subdural empyema, otitic hydrocephalus, Dandy's syndrome, bullousmyringitis, diffuse external otitis, foreign bodies, keratosis obturans,otic neoplasm, otomycosis, trauma, acute barotitis media, acuteeustachian tube obstruction, postsurgical otalgia, cholesteatoma,infections related to an otic surgical procedure.

DETAILED DESCRIPTION

The present embodiments may relate dry compounded medications fortreatment of various ailments, such as inflammatory, ulcerative andpainful conditions of the mucosal surfaces of the upper alimentary canalof a mammal, the respiratory tract, respiratory airways or lungs of amammal, and/or the ear of a mammal.

In one aspect, a dry formulation for the effective administration ofmultiple medications simultaneously for one or more ailments may beprovided. The dry formulations include one or more of the followingactives in combination with pharmaceutically acceptable excipients oradditives: a) at least one antibiotic; b) at least one anti-inflammatorysteroid; and c) at least one antifungal agent.

Formulations containing one or more of these ingredients are typicallyoffered as aqueous solutions or suspension, or for topical applications,creams and gels which contain an aqueous component. Such aqueous-basedformulations containing these active agents are often unstable, however.For example, with regard to formulations intended for oral use, theprimary reason that many typically prescribed compounded “Magic Gargle”or “Magic Mouthwash” formulations have such an offensive taste is due tothe degradation that happens to the medications themselves once mixedinto a large volume bottle containing a host of different ingredients.These formulations are generally a compounded medication that has notbeen reviewed by the FDA for safety or efficacy, and there is no“standard” formula for such a compounded medication.

The dry formulations of medication described herein have an establishedshelf-life of 180 days from the date of compounding. At the time ofadministration, the patient simply mixes the dry formulation, e.g., thecontents of a capsule, with the desired liquid. Since the medication isnot mixed with the liquid until the time of administration, anyoffensive taste (due to degradation) is minimized. Further, since themedication is mixed at the time of administration, it retains its fullpotency.

Other advantage of the dry formulations include the ability to include abroad array of medications available for prescribing, such asantibiotics, antifungals, corticosteroids, antivirals, and localanesthetics. The dry formulations are also portable. For example, thepatient can carry compounded capsules to be mixed at the time ofadministration with the desired liquid. This is particularlyadvantageous for travelers, as patient can simply travel with a smallbottle of capsules and purchase the diluent liquid at his destination.

Finally, in that certain of the dry formulations are suitable fordifferent types of administration. For example a composition containingazithromycin, fluticasone, and fluconazole, described below can beformed into a liquid for oral administration or administration to theear. There is a manufacturing benefit in that a single dry formulationcan be prepared, rather than two specific formulations.

In some embodiments, the dry formulations are encapsulated. They may beencapsulated in a unit dosage form. Encapsulation may be in the form ofa capsule. In general, the capsule is a hard gelatin capsules filledwith the dry powders by introducing the material into one section of thecapsule and capping it with a second section. The capsule contents areremoved for reconstitution into a liquid form for administration.Alternatively, the capsule can be of a type that dissolve in thereconstitution liquid to for a solution or suspension.

The dry formulation, in addition to the active ingredients, containspharmaceutically acceptable excipients or additives. These may include,for example, solvents, surfactants, humectants, preservatives,flavorings, stabilizers (including antioxidants) colorants, and otheradditives used in preparations administered into the oral cavity,intranasally or via the ear.

Other medicinal agents may be added for purposes of alleviating otherundesirable conditions in the mouth. Such agents may include, forexample, anesthetics, analgesics, antibacterial agents, antiviral agentsand emollients.

In some embodiments, the pharmaceutically acceptable excipients oradditives include a base for use in pharmaceutical compounding andmanufacturing of topical preparations. Such base compositions are knownto those skilled in the art. In a preferred embodiment, the base is thePCCA base having the name LOXASPERSE. LOXASPERSE predominantly containsxylitol and polyethylene glycol (PEG).

In one embodiment, the dry formulation includes all of a) at least oneantibiotic; b) at least one anti-inflammatory steroid; and c) at leastone antifungal agent.

It should be understood that the compositions described herein whichemploy a base for use in pharmaceutical compounding and manufacturing oftopical preparations, can be used for the preparation of compositionsfor topical administration for appropriate conditions, for example,keratitis, onychomycosis,

Factors to be considered in choosing a particular anti-inflammatoryagent include cost and absorption of the particular agent. Steroidsparticularly suggested for use in the method of the invention include,but are not limited to: triamcinolone and its derivatives (particularlythe diacetate, hexacetonide, and acetonide), betamethasone and itsderivatives (including particularly the dipropionate, benzoate, sodiumphosphate, acetate, and valerate), dexamethasone and its derivatives(particularly the dipropionate and valerate), flunisolide, prednisoneand its derivatives (particularly its acetate), prednisolone and itsderivatives (particularly its acetate, sodium phosphate and tebutate),methylprednisolone and its derivatives (particularly its acetate andsodium succinate), fluocinolone and its derivatives (particularly theacetonide), diflorasone and its derivatives (particularly thediacetate), halcinonide, desoximetasone (desoxymethasone),diflucortolone and its derivatives (particularly the valerate),flucloronide (fluclorolone acetonide), fluocinonide, fluocortolone,fluprednidene and its derivatives (particularly the acetate),flurandrenolide (flurandrenolone), clobetasol and its derivatives(particularly the propionate), clobetasone and its derivatives(particularly the butyrate), alclometasone, flumethasone and itsderivatives (particularly the pivalate), fluocortolone and itsderivatives (particularly the hexanoate), amcinonide, beclometasone andits derivatives (particularly the dipropionate), fluticasone and itsderivatives (particularly the propionate), difluprednate, prednicarbate,flurandrenolide, mometasone and desonide. Other preferredanti-inflammatory steroids are described herein.

Fluticasone is typically viewed safe in wide variety of patientpopulations due to low anticipated absorption in the in thegastrointestinal tract (GIT) and upper respiratory tract. Betamethasoneis effective in treating inflammation in the oral cavity but does havean anticipated absorption rate of 40-60% based upon literature reviewsin the GIT. Such absorption, if unwanted, would not be problematic witha swish/spit administration, although some absorption could conceivablystill occur.

The effective concentration of drug will vary with the active agent usedand mode of administration. Concentrations will generally fall withinthe 0.1% to 15% range. For example, for fluticasone and its derivativesthe preferred concentration is from about 0.1% to about 10%, morepreferably from about 0.5% to about 5%, and more preferably 1.5%.

The preferred antifungal agents include, but are not limited to,nystatin, clotrimazole, econazole, oxiconazole, ketoconazole,miconazole, ciclopirox, amphotericin B, and sulconazole, terbinafine,fluconazole, itraconazole, and amorolfine. amphotericin B, fluconazole,itraconazole nystatin, voriconazole and flucytosine are particularlypreferred agents. Other preferred antifungal agents are describedherein.

Fluconazole is typically viewed as safe in a wide variety of patientpopulations for a wide variety of reasons and is dosed orally (andswallowed) in pediatric patients.

Expected coverage for various antifungal agents is shown in Table 1below.

TABLE 1 Flucon- Itracon- Voricon- Ampho- azole azole azole tericinNystatin Aspergillus yes yes yes yes flavus Aspergillus yes yes yes yesfumigatus Aspergillus yes yes niger Aspergillus yes yes terreusBlastomyces yes yes yes dermatitidis Candida species yes yes yes yes yesCoccidioides yes yes yes immitis Cryptococcus yes yes yes neoformansFusarium species yes Histoplasma yes yes capsulatum Histoplasma yesduboisii Leishmania yes donovani Leishmania yes infantumParacoccidioides yes yes brasiliensis Scedosporium yes apiospermumSporothrix yes schenckii Trichophyton yes mentagrophytes Trichophytonyes rubrum

Preferred antibiotics include, but are not limited to, amikacin,amoxicillin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin,tobramycin, geldanamycin, herbimycin, carbacephem (loracarbef),ertapenem, doripenem, imipenem, cefadroxil, cefazolin, cefalotin,cephalexin, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime,cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime,ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime,ceftobiprole, clarithromycin, clavulanic acid, clindamycin,colistimethate teicoplanin, azithromycin, dirithromycin, erythromycin,troleandomycin, telithromycin, aztreonam, ampicillin, azlocillin,bacampicillin, carbenicillin, cloxacillin, dicloxacillin,flucloxacillin, mezlocillin, meticillin, nafcillin, norfloxacin,oxacillin, penicillin G, penicillin V, piperacillin, pvampicillin,pivmecillinam, ticarcillin, bacitracin, colistin, colimycin, polymyxinB, ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin,moxifloxacin, ofloxacin, trovafloxacin, grepafloxacin, sparfloxacin,afenide, prontosil, sulfacetamide, metronidazole, sulfamethizole,sulfanilimide, sulfamethoxazole, sulfisoxazole, trimethoprim,trimethoprim-sulfamethoxazole, demeclocycline, doxycycline,oxytetracycline, tetracycline, arsphenamine, chloramphenicol,chlorhexidine, lincomycin, ethambutol, fosfomycin, furazolidone,isoniazid, linezolid, mupirocin, nitrofurantoin, platensimycin,pyrazinamide, quinupristin/dalfopristin, rifampin, thiamphenicol,rifampicin, minocycline, sultamicillin, sulbactam, sulphonamides,mitomycin, spectinomycin, spiramycin, roxithromycin, and meropenem.

Other preferred antibiotics are described herein. Many of these,including azithromycin and sulfamethoxazole/trimethoprim are typicallyviewed as safe in a wide variety of patient populations and are dosedorally (and swallowed) in pediatric patients. Levofloxacin is a thirdgeneration quinolone that is typically reserved for those over 18 yearsof age or those considered “full grown.” Ceftriaxone is a thirdgeneration cephalosporin that is already in powder form and is oftendosed (intravenously) in pediatrics at 100 mg/kg/day (up to 4 grams/day)divided twice daily which would give a prescriber anticipated confidencein dosing the same orally as not being problematic. Meropenem is acarbapenem that is already in powder form and is often dosed(intravenously) in pediatrics at 40 mg/kg IV every 8 hours for ages 3months or older which would give a prescriber anticipated confidence indosing the same orally as not being problematic.

Expected coverage for various antibiotic agents is shown in Tables 2 and3 below.

TABLE 2 Gram Bactroban Ceftriaxone Vancomycin ColistimethateCiprofloxacin Bacteroides anaer yes no no no fragilis Clostridium anaerno yes no no difficile Clostridium anaer no yes no perfringens Chlamydian/a no no no yes pneumoniae Chlamydia n/a no no no psittaci Chlamydian/a no no no trachomatis Mycoplasma n/a no no no yes pneumoniaeAcinetobacter neg no no no ± ± baumannii Acinetobacter neg no no no ± ±calcoaceticus Acinetobacter neg no no no ± ± lwoffii Bartonella neg no ±no yes bacilliformis Bordetella neg no no no no ± pertussis ± Brucellaneg no ± no no ± species Campylobacter neg no no no yes jejuniCitrobacter neg no yes no yes diversus Citrobacter neg no yes no yesfreundii Enterobacter neg no yes no yes yes aerogenes Enterobacter negno yes no yes yes cloacae Enterobacter neg no yes no yes sakazakiiEscherichia neg no yes no yes yes coli Francisella neg no no no yestularensis Haemophilus neg no yes no ducreyi Haemophilus neg no yes noyes influenzae Haemophilus neg yes no no yes parainfluenzae Klebsiellaneg no yes no yes (Calymmato- bacterium) granulomatis Klebsiella neg noyes no yes yes oxytoca Klebsiella neg no yes no yes yes pneumoniaeLegionella neg no no no no yes pneumophila Moraxella neg no yes no noyes catarrhalis Morganella neg no yes no yes morganii Neisseria neg noyes no no yes gonorrhoeae Neisseria neg no yes no no yes meningitidisProteus neg no yes no no yes mirabilis Proteus neg no yes no no yesvulgaris Providencia neg no yes no no yes rettgeri Providencia neg noyes no no yes stuartii Pseudomonas neg no no no yes yes aeruginosaPseudomonas neg no ± no yes yes fluorescens Rickettsiae neg no no no yesSalmonella neg no yes no yes typhi Serratia neg no yes no no yesmarcescens Shigella boydii neg no yes no yes Shigella neg no yes no yesdysenteriae Shigella neg no yes no yes flexneri Shigella sonnei neg noyes no yes Vibrio neg no no no no yes cholerae Yersinia pestis neg no nono yes Corynebacterium pos no no yes no no jeikeium Corynebacterium posno no yes no ± urealyticum Diphtheroids pos no yes no Enterococcus posno yes no ± faecalis Enterococcus pos no yes, not no no faecium VREMethicillin pos yes no yes no no Resistant Staph aureus (MRSA)Peptostrepto- pos yes yes no ± coccus Staphylococcus pos yes yes yes no± aureus (MSSA) Staphylococcus pos yes yes no yes epidermidisStreptococcus pos yes yes no ± agalactiae Streptococcus pos yes yes no ±pneumoniae Streptococcus pos yes yes yes no ± pyogenes Viridans grouppos yes yes no ± streptococci

TABLE 3 Levo- Tobra- Sulfa/ floxacin mycin Doxycycline AzithromycinClindamycin Trim Bacteroides no no ± no yes no fragilis Clostridium nono ± no ± no difficile Clostridium yes no no yes-partial no perfringensChlamydia yes no yes yes ± no pneumoniae Chlamydia no yes yes no nopsittaci Chlamydia no yes yes no no trachomatis Mycoplasma yes no ± yesno no pneumoniae Acinetobacter ± no no no no ± baumannii Acinetobacter ±no ± no no ± calcoaceticus Acinetobacter ± no no no no ± lwoffiiBartonella yes ± yes yes no yes bacilliformis Bordetella ± no yes no yespertussis Brucella ± ± yes no no yes species Campylobacter yes yes yesyes no no jejuni Citrobacter yes yes no no no no diversus Citrobacteryes yes no no no no freundii Enterobacter yes yes ± no no yes aerogenesEnterobacter yes yes ± no no yes cloacae Enterobacter yes yes ± no no nosakazakii Escherichia yes yes ± no no yes coli Francisella yes ± yes nono no tularensis Haemophilus yes yes ± ducreyi Haemophilus yes yes yesyes no ± influenzae Haemophilus yes yes no no parainfluenzae Klebsiellayes yes no no yes (Calymmato- bacterium) granulomatis Klebsiella yes yes± no no yes oxytoca Klebsiella yes yes ± no no yes pneumoniae Legionellayes no yes yes no no pneumophila Moraxella yes yes yes yes no yescatarrhalis Morganella yes ± no no no yes morganii Neisseria yes no ± ±no ± gonorrhoeae Neisseria yes no yes yes no yes meningitidis Proteusyes yes no no no no mirabilis Proteus yes yes no no no no vulgarisProvidencia yes ± no no no ± rettgeri Providencia yes ± no no no ±stuartii Pseudomonas yes yes no no no no aeruginosa Pseudomonas yes yesno no ± fluorescens Rickettsiae yes yes yes no no Salmonella yes ± ± no± typhi Serratia yes yes no no no ± marcescens Shigella yes yes ± ± no ±boydii Shigella yes yes ± ± no ± dysenteriae Shigella yes yes ± ± no ±flexneri Shigella yes yes ± ± no ± sonnei Vibrio yes no yes yes no yescholerae Yersinia pestis yes yes yes ± no yes Corynebacterium no no nojeikeium Corynebacterium ± no ± ± no urealyticum Diphtheroids noEnterococcus yes no no no no no faecalis Enterococcus no no no no no ±faecium Methicillin no no ± no no yes Resistant Staph aureus (MRSA)Peptostreptococcus ± no ± ± yes yes Staphylococcus yes no ± yes yes yesaureus (MSSA) Staphylococcus yes no yes yes yes yes epidermidisStreptococcus yes no ± yes yes yes agalactiae Streptococcus yes no yesyes yes yes pneumoniae Streptococcus yes no ± yes yes ± pyogenesViridans group yes no ± ± yes yes streptococci

I. Formulations and Methods for Topical Oral Delivery

Preferred dry formulations for topical oral delivery includeformulations containing the following combinations of ingredients:

1 to 100 mg azithromycin; 1 to 5 mg fluticasone, and 1 to 50 mgfluconazole.

1 to 100 mg sulfamethoxazole, 1 to 50 mg trimethoprim, 1 to 5 mgfluticasone, and 1 to 50 mg fluconazole.

1 to 150 mg levofloxacin hemihydrate, 1 to 5 mg fluticasone, and 1 to 50mg fluconazole;

-   -   1 to 5 mg fluticasone, and 1 to 50 mg fluconazole; and    -   1 to 5 mg fluticasone.

Any of the above formulations can be dispensed with any of the following

a composition comprising 1 to 1500 mg ceftriaxone, 1 to 5 mgbetamethasone, and 1 to 50 mg fluconazole;

a composition comprising 1 to 1500 mg meropenem, 1 to 5 mgbetamethasone, and 1 to 50 mg fluconazole.

a composition comprising 1 to 50 mg lidocaine hydrochloride, preferably20 mg.

a composition comprising 1 to 200 mg acyclovir.

Acyclovir is an antiviral medication that is not often utilized in thepediatric arena although it can be dosed down to three months of age ina depressed dosing regimen. It can be used in older patients dealingwith viral issues in the oral cavity. Lidocaine is a local anestheticand can be used to help treat pain in the oral cavity. It is typicallyutilized in a swish/spit methodology although swish/swallow is sometimesutilized.

Preferred dry formulations for topical oral administration includeamounts given above in the following ratios:

5% azithromycin, 1.5% fluticasone, and 1.5% fluconazole.

8% sulfamethoxazole, 5% trimethoprim, 1.5% fluticasone, and 1.5%fluconazole.

12.8% levofloxacin hemihydrate, 1.5% fluticasone, and 1.5% fluconazole.

1.5% fluticasone and 1.5% fluconazole.

1.5% fluticasone.

Any of the above formulations can be dispensed with any of thefollowing:

-   -   a) ceftriaxone, betamethasone, and fluconazole. Preferred        amounts are 500 mg ceftriaxone, 0.75 mg betamethasone, and 0.75        mg fluconazole.    -   b) meropenem, betamethasone, and fluconazole. Preferred amounts        are 500 mg meropenem, 0.75 mg betamethasone, and 0.75 mg        fluconazole.    -   c) lidocaine. A preferred amount is 20 mg lidocaine        hydrochloride.    -   d) acyclovir. A preferred amount is 200 mg acyclovir.

In preferred embodiments, the dry formulation for topical oraladministration does not contain an antihistamine.

In some embodiments, the formulations of the invention comprise thelisted active ingredients. In other embodiments the formulations of theinvention consist of the listed ingredients and a pharmaceuticallyacceptable carrier. The phrase “consisting essentially of” limits acomposition to the specified materials or steps and those additional,undefined components that do not materially affect the basic and novelcharacteristic(s) of the composition, such as, for example, additionalactive ingredients. In still other embodiments, the formulations of theinvention consist of the listed active ingredients and apharmaceutically acceptable carrier. “Consisting of” refers to theinclusion of exactly one element of a number or list of elements.

Also included is a method of preparing an orally administrableformulation comprising forming a dry formulation for oral administrationinto an oral rinse or an oral solution. For example, the compositionsdescribed herein may be incorporated into mouthwash formulations fororal administration as an oral rinse. The dry formulation compositionsmay be combined with any known mouthwash base material.

The oral rinse or solution base material may comprise a diphenhydramineelixir such as Benadryl®, or a generic equivalent. In some embodiments,the concentration of diphenhydramine in the elixir is 12.5 mg/5 mL. Thebase material may also comprise aluminium hydroxide and/or magnesiumhydroxide, including Maalox® (MgOH & AlOH; 40 mg/ml), or a genericequivalent, Mylanta, or a generic equivalent. Other agents that can beincluded in the base material include a local anesthetic such aslidocaine or Dyclone, nystatin, sucralfate, Kaopectate, allopurinol,vitamin E, beta-carotene, Kamillosan liquid, aspirin,antiprostaglandins, prostaglandins, MGI 209 (marketed as Oratect Gel),silver nitrate, and antiviral agents such as acyclovir. Other suitableoral rinse base material may include Prevident@ or Phos-Flur@ rinses.

In the case of an oral rinse, the patient is instructed to mix thecontents of 1 capsule or vial with about 10 mL of the desired basematerial. The preparation is to be swished around in the mouth for anappropriate length of time, e.g., at least about 1-3 minutes, thenexpectorated. This is also known a swish/spit methodology.

In the case of an oral solution, the patient is instructed to mix thecontents of 1 capsule or vial with about 10 mL of the desired basematerial. The preparation is to be swished around in the mouth for anappropriate length of time, e.g., at least about 1-3 minutes, thenswallowed. Typically, the administration is three times daily. This isalso known a swish/swallow methodology.

The oral rinses and solutions described are useful for treating avariety of disorders affecting the mucosal surfaces of the upperalimentary canal, including the oral mucosa, lips, and perioral regionof the face of a mammal, preferably a human. The oral mucosa is themucous membrane epithelium of the mouth. It can be divided into threecategories—the masticatory mucosa, the lining mucosa, and thespecialized mucosa. The lips surround the mouth and the entrance of theoral cavity, and the perioral region includes the skin surrounding thelips and mouth.

Medical conditions in this area can be problematical, inconvenient totreat, and painful to endure. Furthermore, the impact of oral diseasesdoes not stop at the mouth and teeth. A growing body of evidence haslinked oral health, particularly periodontal (gum) disease, to severalchronic diseases including diabetes, heart disease, and stroke.

Dental caries is most common chronic disease in the world. Tooth decayaffects more than 1 out of 4 US children ages 2 to 5, 1 out of 2 in USchildren ages 12 to 15. Oral diseases cause pain and disability formillions of Americans. Gum disease and other oral issues typicallycaused by presence of acid-producing bacteria in the mouth and typicallyworsens as age increases. These conditions and others are contemplatedfor treatment with the formulations of the present invention.

For example, cheilitis involves the inflammation of the lip. The typesof cheilitis are exfoliative, allergic, actinic, glandular, bacterial,and others. Other common superficial lesions of the oral mucosa, lips,and perioral region include candidiasis, recurrent herpes labialis,recurrent aphthous stomatitis, erythema migrans, hairy tongue, lichenplanus, eosinophilic esophogitis, and ulcer.

The condition treated may be caused by or the result of anantineoplastic therapy, such as chemotherapy or radiation therapy. Thecondition may also be caused by or the result of gingivitis. Thecondition may also be caused by or the result of a bacterial, viral orfungal infection.

II. Formulations and Methods for Topical Nasal/Upper RespiratoryDelivery

Dry formulations for nasal or upper respiratory delivery includeformulations containing the following combinations of ingredients:

1 to 150 mg levofloxacin, 1 to 200 mg mupirocin, 1 to 5 mg fluticasone,and 1 to 100 mg itraconazole.

1 to 150 mg levofloxacin, 1 to 5 mg fluticasone, and 1 to 100 mgitraconazole.

1 to 150 mg levofloxacin, 1 to 5 mg fluticasone, and 1 to 15 mgamphotericin B.

1 to 150 mg tobramycin, 1 to 5 mg fluticasone, and 1 to 100 mgitraconazole.

1 to 150 mg tobramycin, 1 to 5 mg fluticasone, and 1 to 15 mgamphotericin B.

1 to 200 mg mupirocin, 1 to 5 mg fluticasone, and 1 to 100 mgitraconazole.

1 to 200 mg mupirocin, 1 to 5 mg fluticasone, and 1 to 15 mgamphotericin B.

1 to 100 mg vancomycin hydrochloride, 1 to 5 mg fluticasone, and 1 to100 mg itraconazole.

1 to 100 mg vancomycin hydrochloride, 1 to 5 mg fluticasone, and 1 to 15mg amphotericin B.

1 to 50 mg tobramycin, 1 to 200 mg mupirocin.

1 to 5 mg fluticasone and 1 to 15 mg amphotericin B.

1 to 5 mg fluticasone and 1 to 100 mg itraconazole.

In some embodiments of these dry formulations, the pharmaceuticallyacceptable excipients or additives include a base for use inpharmaceutical compounding and manufacturing of topical preparations.

Preferred dry formulations for nasal or upper respiratory deliveryinclude:

levofloxacin hemihydrate, 10% mupirocin, 1.5% fluticasone, and 5%itraconazole.

12.8% levofloxacin hemihydrate, 1.5% fluticasone, and 5% itraconazole.

12.8% levofloxacin hemihydrate, 1.5% fluticasone, and 1% amphotericin B.

16% tobramycin, 1.5% fluticasone, and 5% itraconazole.

16% tobramycin, 1.5% fluticasone, and 1% amphotericin B.

10% mupirocin, 1.5% fluticasone, and 5% itraconazole.

10% mupirocin, 1.5% fluticasone, and 1% amphotericin B.

5.15% vancomycin hydrochloride, 1.5% fluticasone, and 5% itraconazole.

5.15% vancomycin hydrochloride, 1.5% fluticasone, and 1% amphotericin B.

16% tobramycin, 20% mupirocin.

1.5% fluticasone and 1% amphotericin B.

1.5% fluticasone and 5% itraconazole.

The disclosure also provides a dry formulation or nasal or upperrespiratory delivery comprising one or more of the following actives incombination with pharmaceutically acceptable excipients or additives: a)at least one leukotriene receptor antagonist; b) at least oneanti-inflammatory steroid; and c) at least one non-sedativeantihistamine.

In one embodiment, the formulation comprises the following actives: 1 to5 mg montelukast, 1 to 5 mg fluticasone, and 1 to 5 mg levocetirizine.

In other embodiments, the formulation comprises the following actives:0.3% montelukast, 1.5% fluticasone, 0.2% levocetirizine dihydrochloride.

Also included is a method for preparing an intranasally administrableformulation comprising forming a dry formulation into a nasal solutionor suspension with a diluent suitable for intranasal delivery of activeingredients. For example, a liquid spray or a nebulized powder allowingthe active ingredient to be delivered into the nasal or nasopharyngealcavity is contemplated. It is noted that the dry formulations describedherein are not intended for administration as powders.

Diluents for the preparation of intranasally administrable formulationsare known to those skilled in the art, for example 0.9% sodium chloride,which is available in vials and with a prescription or over the counter.

In some embodiments, the formed composition is administrable by a nasalnebulizer. Suitable devices include the NASONEB® system and theSINUSTAR® system. Other suitable devices include Micromist (Hudson RC1),Pulmo-Aide (Devilbiss), Sidestream, MS 2400 (Invacare), and Pan LC Star(Pari Respiratory equipment.

In other embodiments, the typical mode of administration is in flushform or liquid stream form. An example of suitable sinus rinse deliverymechanisms include the NeilMed® Sinus Rinse Bottle, a medical syringe ofabout 20 to 60 ml in size, and other squeeze bottle irrigation devices.

Typically, the intranasally administrable formulation is administeredtwo or three times a day.

Also included is a method for treating inflammatory, ulcerative andpainful conditions of the respiratory tract, respiratory airways orlungs of a mammal comprising administering an intranasally administrableformulation as described herein. The administering can be any suitablemeans, including inhalation, spraying, liquid stream lavage, nebulizing,or nasal irrigation. Further, administration can be directed to thesinus cavity or the lungs, for instance.

The inflammatory, ulcerative and painful condition of the respiratorytract, respiratory airways or lungs can include a condition caused by abacterial, viral, or fungal infection, including a pseudomonas infectionor a MRSA infection, influenza and the common cold. Other conditionscontemplated include an upper respiratory tract infection lowerrespiratory tract infection, cystic fibrosis, bronchiolitis,bronchiectasis, tracheobronchitis, pneumonia (includingventilator-associated pneumonia, pneumonitis, dyspnea, cough,(recurrent) wheezing, asthma, nasal polyopsis, allergic rhinitis, upperrespiratory infections (Common cold), pulmonary sarcoidosis, anosmia,olfactory (smell) loss, sinus ostia stenosis, aspergilliosis, pulmonaryinvasive fungal infections, sinusitis, chronic rhinosinusitis,nosocomial lung infections.

III. Formulations and Methods for Aural Delivery

Dry formulations for aural delivery include formulations containing thefollowing combinations of ingredients:

1 mg to 50 mg azithromycin, 1 mg to 5 mg fluticasone, and 1 mg to 50 mgfluconazole.

1 mg to 180 mg sulfamethoxazole, 1 mg to 50 mg trimethoprim, 1 mg to 5mg fluticasone, and 1 mg to 50 mg fluconazole.

1 mg to 150 mg levofloxacin hemihydrate, 1 mg to 5 mg fluticasone, and 1mg to 50 mg fluconazole.

1 mg to 5 mg fluticasone and 1 mg to 50 mg fluconazole.

1 to 100 mg vancomycin hydrochloride and 1 to 200 mg mupirocin.

Preferred dry formulations for aural delivery include:

5% azithromycin, 1.5% fluticasone, and 1.5% fluconazole.

8% sulfamethoxazole, 5% trimethoprim, 1.5% fluticasone, and 1.5%fluconazole.

12.8% levofloxacin hemihydrate, 1.5% fluticasone, and 1.5% fluconazole.

1.5% fluticasone and 1.5% fluconazole.

5.15% vancomycin hydrochloride, 20% mupirocin,

Any of the above formulations can be dispensed with any of thefollowing:

a) ceftriaxone, betamethasone, and fluconazole. Preferred amounts are500 mg ceftriaxone, 0.75 mg betamethasone, and 0.75 mg fluconazole.

Also included is a method of preparing a formulation for auraladministration comprising forming a dry formulation as described hereininto a solution or suspension with a diluent suitable for otic deliveryof active ingredient. Diluents for the preparation of formulations foraural administration are known to those skilled in the art and aresimilar to those described above for the preparation of intranasallyadministrable formulations.

The resulting solution or suspension can be administered to the ear orear canal. For example, the solution or suspension can be drawn into asyringe and then dispensed into the ear canal. For such administration,the solution should not be cold. For instance, the solution can bewarmed by holding the container in the hand for one or two minutes toavoid dizziness which may result from the instillation of a coldsolution. The patient should lie with the affected ear upward, and thenthe medication should be instilled. The ear canal should be completelyfilled to ensure that medication is allowed to touch all areas of theear canal. The process can be repeated for other ear if needed.

Also included is a method for treating inflammatory, ulcerative andpainful conditions of the ear of a mammal comprising administering tosaid mammal a formulation for aural administration as described herein.As noted the administering may be by instillation of the solution orsuspension into the ear canal. In general, the administering is two tothree times daily.

The inflammatory, ulcerative and painful conditions of the ear caninclude, for example, otitis externa, otitis media, otorrhea, acutemastoiditis, otosclerosis, otic pain, otic bleeding, otic inflammation,Lermoyez's syndrome, Meniere's disease, vestibular neuronitis, benignparoxysmal positional vertigo, herpes zoster oticus, Ramsay Hunt'ssyndrome, viral neuronitis, ganglionitis, geniculate herpes,labyrinthitis, purulent labyrinthitis, perilymph fistulas, presbycusis,drug-induced ototoxicity, acoustic neuromas, aerotitis media, infectiousmyringitis, bullous myringitis, squamous cell carcinoma, basal cellcarcinoma, pre-cancerous otic conditions, nonchromaffin paragangliomas,chemodectomas, glomus jugulare tumors, glomus tympanicum tumors,perichondritis, aural eczematoid dermatitis, malignant external otitis,subperichondrial hematoma, ceruminomas, impacted cerumen, sebaceouscysts, osteomas, keloids, otalgia, tinnitus, vertigo, tympanic membraneinfection, tympanitis, otic furuncles, petrositis, conductive andsensorineural hearing loss, epidural abscess, lateral sinus thrombosis,subdural empyema, otitic hydrocephalus, Dandy's syndrome, bullousmyringitis, diffuse external otitis, foreign bodies, keratosis obturans,otic neoplasm, otomycosis, trauma, acute barotitis media, acuteeustachian tube obstruction, postsurgical otalgia, cholesteatoma, andinfections related to an otic surgical procedure.

IV. Representative Method of Compounding

A method of compounding may include combining the active ingredientswith a base composition and shaking or otherwise mixing the combinedingredients, sifting the resulting powder mixture through a fine meshstrainer, mixing the powdered mixture until a homogeneous powderresults. A suitable mixer for this purpose is a TURBULA@ mixer, which isable to mix powdery substances with differing specific weights andparticle sizes. The mixing is generally performed for about one hour.The resulting homogeneous mixture can be encapsulated into a suitablecapsule, for example a #00 size capsule.

VI. Exemplary Storage Characteristics

The dry formulations discussed herein exhibit excellent storagecharacteristics. The dry formulations described herein are stable for atleast about 6 months, or about 180 days.

Certain preferred features are provided by the following numberedclauses:

Clause 1. A dry formulation comprising one or more of the followingactives in combination with pharmaceutically acceptable excipients oradditives:

-   -   a) at least one antibiotic;    -   b) at least one anti-inflammatory steroid; and    -   c) at least one antifungal agent.

Clause 2. The dry formulation of clause 1, wherein all of actives (a) to(c) are included.

Clause 3. The dry formulation of clause 1, wherein the dry formulationis formulated as a capsule.

Clause 4. The dry formulation of clause 1, wherein the pharmaceuticallyacceptable excipients or additives comprise: at least one solvent, atleast one emollient, at least one humectant, at least one preservative,and at least one emulsifier; and optionally including an acid, base, orbuffering agent to adjust the pH.

Clause 5. The dry formulation of clause 1, wherein the pharmaceuticallyacceptable excipients or additives include a base for use inpharmaceutical compounding and manufacturing of topical preparations.

Clause 6. The dry formulation of clause 1, wherein the dry formulationdoes not contain an antihistamine

Clause 7. The dry formulation of clause 1, wherein the dry formulationis stable for 180 days.

Clause 8. The dry formulation of clause 1 comprising the followingactives: 5% azithromycin, 1.5% fluticasone, and 1.5% fluconazole.

Clause 9. The dry formulation of clause 1 comprising the followingactives: 8% sulfamethoxazole, 5% trimethoprim, 1.5% fluticasone, and1.5% fluconazole.

Clause 10. The dry formulation of clause 1 comprising the followingactives: 12.8% levofloxacin hemihydrate, 1.5% fluticasone, and 1.5%fluconazole.

Clause 11. The dry formulation of clause 1 comprising the followingactives: 1.5% fluticasone and 1.5% fluconazole.

Clause 12. The dry formulation of clause 1 comprising the followingactives: 1.5% fluticasone, wherein the pharmaceutically acceptableexcipients or additives include a base for use in pharmaceuticalcompounding and manufacturing of topical preparations.

Clause 13. A method of preparing an orally administrable formulationcomprising forming the dry formulation of clause 1 into an oral rinse oran oral solution.

Clause 14. The method of clause 13, wherein the oral rinse comprisesdiphenhydramine.

Clause 15. The method of clause 13, wherein the oral solution comprisesaluminium hydroxide, magnesium hydroxide and simethicone.

Clause 16. The method of clause 13, further comprising forming a localanesthetic into the oral rinse or oral solution.

Clause 17. The method of clause 16, wherein the local anesthetic islidocaine.

Clause 18. The method of clause 13, further comprising forming anantiviral agent into the oral rinse or oral solution.

Clause 19. The method of clause 18, wherein the antiviral agent isacyclovir.

Clause 20. An orally administrable formulation obtained by the method ofclause 13.

Clause 21. A method for treating inflammatory, ulcerative and painfulconditions of mucosal surfaces of the upper alimentary canal of a mammalcomprising administering to said patient the orally administrableformulation of clause 20.

Clause 22. The method of clause 21, wherein the orally administrableformulation is an oral rinse and wherein the method comprises:

-   -   (1) swishing the oral rinse formulation; and    -   (2) expectorating the oral rinse formulation.

Clause 23. The method of clause 21, wherein the orally administrableformulation is an oral solution and wherein the method comprises:

-   -   (1) swishing the oral solution; and    -   (2) swallowing the oral solution.

Clause 24. The method of clause 21, wherein said mammal is a humanClause 25. The method of clause 21, wherein the condition is mucositis.

Clause 26. The method of clause 21, wherein the condition is aphthousstomatitis.

Clause 27. The method of clause 21, wherein the condition is oral lichenplanus.

Clause 28. The method of clause 21, wherein the condition iseosinophilic esophogitis

Clause 29. The method of clause 21, wherein the condition is an ulcer.

Clause 30. The method of clause 21, wherein the condition is caused byantineoplastic therapy.

Clause 31. The method of clause 30, wherein said antineoplastic therapyis radiation therapy.

Clause 32. The method of clause 30, wherein said antineoplastic therapyis chemotherapy.

Clause 33. The method of clause 21, wherein the condition is the resultof gingivitis.

Clause 34. The method of clause 21, wherein the condition is the resultof tooth extraction.

Clause 35. The method of clause 21, wherein the condition is caused by abacterial, viral, or fungal infection.

Clause 36. The method of clause 35, wherein the infection is selectedfrom the group consisting of candidias and herpes labialis

Clause 37. The method of clause 35, wherein the condition is erythemamigrans.

Clause 38. The dry formulation of clause 1 comprising the followingactives: 12.8% levofloxacin hemihydrate, 10% mupirocin, 1.5%fluticasone, and 5% itraconazole.

Clause 39. The dry formulation of clause 1 comprising the followingactives: 12.8% levofloxacin hemihydrate, 1.5% fluticasone, and 5%itraconazole.

Clause 40. The dry formulation of clause 1 comprising the followingactives: 12.8% levofloxacin hemihydrate, 1.5% fluticasone, and 1%amphotericin B.

Clause 41. The dry formulation of clause 1 comprising the followingactives: 16% tobramycin, 1.5% fluticasone, and 5% itraconazole.

Clause 42. The dry formulation of clause 1 comprising the followingactives: 16% tobramycin, 1.5% fluticasone, and 1% amphotericin B.

Clause 43. The dry formulation of clause 1 comprising the followingactives: 10% mupirocin, 1.5% fluticasone, and 5% itraconazole.

Clause 44. The dry formulation of clause 1 comprising the followingactives: 10% mupirocin, 1.5% fluticasone, and 1% amphotericin B.

Clause 45. The dry formulation of clause 1 comprising the followingactives: 5.15% vancomycin hydrochloride, 1.5% fluticasone, and 5%itraconazole.

Clause 46. The dry formulation of clause 1 comprising the followingactives: 5.15% vancomycin hydrochloride, 1.5% fluticasone, and 1%amphotericin B.

Clause 47. The dry formulation of clause 1, comprising the followingactives: 16% tobramycin, 20% mupirocin, wherein the pharmaceuticallyacceptable excipients or additives include a base for use inpharmaceutical compounding and manufacturing of topical preparations.

Clause 48. The dry formulation of clause 1 comprising the followingactives: 1.5% fluticasone and 1% amphotericin B, wherein thepharmaceutically acceptable excipients or additives include a base foruse in pharmaceutical compounding and manufacturing of topicalpreparations.

Clause 49. The dry formulation of clause 1 comprising the followingactives: 1.5% fluticasone and 5% itraconazole, wherein thepharmaceutically acceptable excipients or additives include a base foruse in pharmaceutical compounding and manufacturing of topicalpreparations.

Clause 50. A method of preparing an intranasally administrableformulation comprising forming the dry formulation of clause 1 into anasal solution or suspension with a diluent suitable for intranasaldelivery of active ingredients.

Clause 51. An intranasally administrable formulation obtained by themethod of clause 50.

Clause 52. A method for treating inflammatory, ulcerative and painfulconditions of the respiratory tract, respiratory airways or lungs of amammal comprising administering to said mammal the intranasallyadministrable formulation of clause 51.

Clause 53. The method of clause 51, wherein the intranasallyadministrable formulation is administered by a method selected from thegroup consisting of inhalation, spraying, liquid stream lavage,nebulizing, and nasal irrigation.

Clause 54. The method of clause 53, wherein the administering is to thesinus cavity.

Clause 55. The method of clause 53, wherein the administering is to thelungs.

Clause 56. The method of clause 53, wherein the administering two orthree times a day.

Clause 57. The method of clause 53, wherein the method is nebulizing.

Clause 58. The method of clause 53, wherein the method is nasalirrigation.

Clause 59. The method of clause 52, wherein said mammal is a human.

Clause 60. The method of clause 52, wherein the condition is caused by abacterial, viral, or fungal infection.

Clause 61. The method of clause 60, wherein the infection is apseudomonas infection.

Clause 62. The method of clause 60, wherein the infection is a MRSAinfection.

Clause 63. The method of clause 52, wherein the condition is selectedfrom the group consisting of an upper respiratory tract infection lowerrespiratory tract infection, bronchiolitis, pneumonia, dyspnea, cough,(recurrent) wheezing and asthma.

Clause 64. A dry formulation comprising one or more of the followingactives in combination with pharmaceutically acceptable excipients oradditives:

-   -   a) at least one leukotriene receptor antagonist;    -   b) at least one anti-inflammatory steroid; and    -   c) at least one non-sedative antihistamine.

Clause Clause 65. The dry formulation of clause 64 comprising thefollowing actives: 0.3% montelukast, 1.5% fluticasone, 0.2%levocetirizine dihydrochloride.

Clause 66. The dry formulation of clause 64, comprising the followingactives: 5.15% vancomycin hydrochloride, 20% mupirocin, wherein thepharmaceutically acceptable excipients or additives include a base foruse in pharmaceutical compounding and manufacturing of topicalpreparations.

Clause 67. A method of preparing a formulation for aural administrationcomprising forming the dry formulation of clause 64 into a solution orsuspension with a diluent suitable for otic delivery of activeingredients.

Clause 68. A formulation for aural administration obtained by the methodof clause 67.

Clause 69. A method for treating inflammatory, ulcerative and painfulconditions of the ear of a mammal comprising administering to saidmammal the formulation for aural administration of clause 68.

Clause 70. The method of clause 68, wherein the formulation for auraladministration is administered by instillation of the solution orsuspension into the ear canal.

Clause 71. The method of clause 68, wherein the administering threetimes a day.

Clause 72. The method of clause 68, wherein the condition is selectedfrom the group consisting of otitis externa, otitis media, otorrhea,acute mastoiditis, otosclerosis, otic pain, otic bleeding, oticinflammation, Lermoyez's syndrome, Meniere's disease, vestibularneuronitis, benign paroxysmal positional vertigo, herpes zoster oticus,Ramsay Hunt's syndrome, viral neuronitis, ganglionitis, geniculateherpes, labyrinthitis, purulent labyrinthitis, perilymph fistulas,presbycusis, drug-induced ototoxicity, acoustic neuromas, aerotitismedia, infectious myringitis, bullous myringitis, squamous cellcarcinoma, basal cell carcinoma, pre-cancerous otic conditions,nonchromaffin paragangliomas, chemodectomas, glomus jugulare tumors,glomus tympanicum tumors, perichondritis, aural eczematoid dermatitis,malignant external otitis, subperichondrial hematoma, ceruminomas,impacted cerumen, sebaceous cysts, osteomas, keloids, otalgia, tinnitus,vertigo, tympanic membrane infection, tympanitis, otic furuncles,petrositis, conductive and sensorineural hearing loss, epidural abscess,lateral sinus thrombosis, subdural empyema, otitic hydrocephalus,Dandy's syndrome, bullous myringitis, diffuse external otitis, foreignbodies, keratosis obturans, otic neoplasm, otomycosis, trauma, acutebarotitis media, acute eustachian tube obstruction, postsurgicalotalgia, cholesteatoma, infections related to an otic surgicalprocedure.

The present invention may be embodied in other forms without departingfrom the spirit or essential attributes thereof and, accordingly,reference should be had to the following claims rather than theforegoing specification as indicating the scope of the invention.Further, the illustrations of arrangements described herein are intendedto provide a general understanding of the various embodiments, and theyare not intended to serve as a complete description. Many otherarrangements will be apparent to those of skill in the art uponreviewing the above description. Other arrangements may be utilized andderived therefrom, such that logical substitutions and changes may bemade without departing from the scope of this disclosure.

This disclosure is intended to cover any and all adaptations orvariations of various embodiments and arrangements of the invention.Combinations of the above arrangements, and other arrangements notspecifically described herein, will be apparent to those of skill in theart upon reviewing the above description. Therefore, it is intended thatthe disclosure not be limited to the particular arrangement(s) disclosedas the best mode contemplated for carrying out this invention, but thatthe invention will include all embodiments and arrangements fallingwithin the scope of the appended claims.

The Abstract of the Disclosure is provided to comply with 37 C.F.R.§1.72(b), requiring an abstract that will allow the reader to quicklyascertain the nature of the technical disclosure. It is submitted withthe understanding that it will not be used to interpret or limit thescope or meaning of the claims.

EXAMPLES Example 1 Preparation of a Dry Formulation of 5% Azithromycin,1.5% Fluticasone, and 1.5% Fluconazole

5 g azithromycin dihydrate powder, 1.5 g fluticasone 20% aliquot and 1.5g fluconazole are combined with 61.7 g PCCA LOXASPERSE base and shakenwell. The mixture is sifted through a fine mesh strainer. The mixture isthen placed in a TURBULA® mixer and mixed for one hour. The resultinghomogeneous powder is encapsulated into a capsule sized #00. Eachcapsule contains approximately 0.05 g azithromycin, 0.015 g fluticasone,0.015 g fluconazole and 0.617 g LOXASPERSE.

Example 2 Preparation of a Dry Formulation of 8% Sulfamethoxazole, 5%Trimethoprim, 1.5% Fluticasone, and 1.5% Fluconazole

8 g sulfamethoxazole, 5 g micronized trimethoprim, 1.5 g fluticasone 20%aliquot and 1.5 g fluconazole are combined with 48.2 g PCCA LOXASPERSEbase and mixed and encapsulated according to the procedure of Example 1.Each capsule contains approximately 0.08 g sulfamethoxazole, 0.05 gtrimethoprim, 0.015 g fluticasone, 0.015 g fluconazole and 0.482 gLOXASPERSE.

Example 3 Preparation of a Dry Formulation of 12.8% LevofloxacinHemihydrate, 1.5% Fluticasone, and 1.5% Fluconazole

12.8 g levofloxacin hemihydrate, 1.5 g fluticasone 20% aliquot and 1.5 gfluconazole are combined with 46.5 g PCCA LOXASPERSE base and mixed andencapsulated according to the procedure of Example 1. Each capsulecontains approximately 0.128 g levofloxacin hemihydrate, 0.015 gfluticasone, 0.015 g fluconazole and 0.465 g LOXASPERSE. 5.12 mglevofloxacin hemihydrate equals 5 mg levofloxacin.

Example 4 Preparation of a Dry Formulation of 1.5% Fluticasone and 1.5%Fluconazole

1.5 g fluticasone 20% aliquot and 1.5 g fluconazole are combined with67.7 g PCCA LOXASPERSE base and mixed and encapsulated according to theprocedure of Example 1. Each capsule contains approximately 0.015 gfluticasone, 0.015 g fluconazole and 0.677 g LOXASPERSE.

Example 5 Preparation of a Dry Formulation of 1.5% Fluticasone

1.5 g fluticasone 20% aliquot is combined with 69.2 g PCCA LOXASPERSEbase and mixed and encapsulated according to the procedure of Example 1.Each capsule contains approximately 0.015 g fluticasone and 0.692 gLOXASPERSE.

Example 6 Preparation of a Dry Formulation of 12.8% LevofloxacinHemihydrate, 10% Mupirocin, 1.5% Fluticasone, and 5% Itraconazole

12.8 g levofloxacin hemihydrate, 10 g mupirocin, 1.5 g fluticasone 20%aliquot and 5 g micronized itraconazole are combined with 14.3 g PCCALOXASPERSE base and mixed and encapsulated according to the procedure ofExample 1. Each capsule contains approximately 0.128 g levofloxacinhemihydrate, 0.1 g mupirocin, 0.015 g fluticasone, 0.05 g itraconazoleand 0.143 g LOXASPERSE.

Example 7 Preparation of a Dry Formulation of 12.8% LevofloxacinHemihydrate, 1.5% Fluticasone, and 5% Itraconazole

12.8 g levofloxacin hemihydrate, 1.5 g fluticasone 20% aliquot and 5 gmicronized itraconazole are combined with 43.7 g PCCA LOXASPERSE baseand mixed and encapsulated according to the procedure of Example 1. Eachcapsule contains approximately 0.128 g levofloxacin hemihydrate, 0.015 gfluticasone, 0.05 g itraconazole and 0.437 g LOXASPERSE.

Example 8 Preparation of a Dry Formulation of 12.8% LevofloxacinHemihydrate, 1.5% Fluticasone, and 1% Amphotericin B

12.8 g levofloxacin hemihydrate, 1.5 g fluticasone 20% aliquot and 1 gamphotericin B (oral grade) are combined with 47 g PCCA LOXASPERSE baseand mixed and encapsulated according to the procedure of Example 1. Eachcapsule contains approximately 0.128 g levofloxacin hemihydrate, 0.015 gfluticasone, 0.01 g amphotercin B and 0.470 g LOXASPERSE.

Example 9 Preparation of a Dry Formulation of 16% Tobramycin, 1.5%Fluticasone, and 5% Itraconazole

16 g tobramycin, 1.5 g fluticasone 20% aliquot, 5 g micronizeditraconazole and 6.18 g citric acid monohydrate are combined with 31.3 gPCCA LOXASPERSE base and mixed and encapsulated according to theprocedure of Example 1. The citric acid is ground prior to mixing withthe rest of the ingredients. Each capsule contains approximately 0.16 gtobramycin, 0.015 g fluticasone, 0.05 g itraconazole 0.0618 g citricacid and 0.313 g LOXASPERSE.

Example 10 Preparation of a Dry Formulation of 16% Tobramycin, 1.5%Fluticasone, and 1% Amphotericin B

16 g tobramycin, 1.5 g fluticasone 20% aliquot, 1 g amphotericin B (oralgrade) and 6.18 g citric acid monohydrate are combined with 34.6 g PCCALOXASPERSE base and mixed and encapsulated according to the procedure ofExample 1. The citric acid is ground prior to mixing with the rest ofthe ingredients. Each capsule contains approximately 0.16 g tobramycin,0.015 g fluticasone, 0.01 g amphotercin B, 0.0618 g citric acid and0.346 g LOXASPERSE.

Example 11 Preparation of a Dry Formulation of 10% Mupirocin, 1.5%Fluticasone, and 5% Itraconazole

10 g mupirocin, 1.5 g fluticasone 20% aliquot and 5 g micronizeditraconazole are combined with 43 g PCCA LOXASPERSE base and mixed andencapsulated according to the procedure of Example 1. Each capsulecontains approximately 0.1 g mupirocin, 0.015 g fluticasone, 0.05 gitraconazole and 0.43 g LOXASPERSE.

Example 12 Preparation of a Dry Formulation of 10% Mupirocin, 1.5%Fluticasone, and 1% Amphotericin B

10 g mupirocin, 1.5 g fluticasone 20% aliquot and 1 g amphotericin B(oral grade) are combined with 37.9 g PCCA LOXASPERSE base and mixed andencapsulated according to the procedure of Example 1. Each capsulecontains approximately 0.1 g mupirocin, 0.015 g fluticasone, 0.05 gitraconazole and 0.379 g LOXASPERSE.

Example 13 Preparation of a Dry Formulation of 5.15% VancomycinHydrochloride, 1.5% Fluticasone, and 5% Itraconazole

5.15 g vancomycin hydrochloride, 1.5 g fluticasone 20% aliquot and 5 gmicronized itraconazole are combined with 59 g PCCA LOXASPERSE base andmixed and encapsulated according to the procedure of Example 1. 1.03 gvancomycin hydrochloride equals 1 g vancomycin. Each capsule containsapproximately 0.515 g vancomycin hydrochloride, 0.015 g fluticasone,0.05 g itraconazole and 0.59 g LOXASPERSE.

Example 14 Preparation of a Dry Formulation of 5.15% VancomycinHydrochloride, 1.5% Fluticasone, and 1% Amphotericin B

5.15 g vancomycin hydrochloride, 1.5 g fluticasone 20% aliquot and 1 gamphotericin B (oral grade) are combined with 62.3 g PCCA LOXASPERSEbase and mixed and encapsulated according to the procedure of Example 1.Each capsule contains approximately 0.515 g vancomycin hydrochloride,0.015 g fluticasone, 0.05 g itraconazole and 0.623 g LOXASPERSE.

Example 15 Preparation of a Dry Formulation of 16% Tobramycin and 20%Mupirocin

16 g tobramycin, 20 g mupirocin and 6.18 g citric acid monohydrate arecombined, mixed and encapsulated according to the procedure ofExample 1. The citric acid is ground prior to mixing with the rest ofthe ingredients. Each capsule contains approximately 0.16 g tobramycin,0.2 g mupirocin, and 0.0618 g citric acid.

Example 16 Preparation of a Dry Formulation of 1.5% Fluticasone and 1%Amphotericin B

1.5 g fluticasone 20% aliquot and 1 g amphotericin B (oral grade) arecombined with 67.2 g PCCA LOXASPERSE base and mixed and encapsulatedaccording to the procedure of Example 1. Each capsule containsapproximately 0.1 g mupirocin, 0.015 g fluticasone, 0.05 g itraconazoleand 0.672 g LOXASPERSE.

Example 17 Preparation of a Dry Formulation of 1.5% Fluticasone and 5%Itraconazole, Wherein the Pharmaceutically Acceptable Excipients orAdditives Include a Base for Use in Pharmaceutical Compounding andManufacturing of Topical Preparations

1.5 g fluticasone 20% aliquot and 5 g micronized itraconazole arecombined with 64 g PCCA LOXASPERSE base and mixed and encapsulatedaccording to the procedure of Example 1. 1.03 g vancomycin hydrochlorideequals 1 g vancomycin. Each capsule contains approximately 0.515 gvancomycin hydrochloride, 0.015 g fluticasone, 0.05 g itraconazole and0.64 g LOXASPERSE.

Example 18 Preparation of a Dry Formulation of 0.3% Montelukast, 1.5%Fluticasone, 0.2% Levocetirizine Dihydrochloride

0.3 g montelukast sodium, 0.2 g levocetirizine dihydrochloride and 1.5 gfluticasone 20% aliquot are combined with 68.7 g PCCA LOXASPERSE baseand mixed and encapsulated according to the procedure of Example 1. Eachcapsule contains approximately 0.003 g montelukast sodium, 0.002 glevocetirizine dihydrochloride 0.015 g fluticasone, and 0.64 gLOXASPERSE.

Example 19 Preparation of a Dry Formulation of 5.15% VancomycinHydrochloride, 20% Mupirocin

5.15 g vancomycin hydrochloride and 20 g mupirocin are combined withPCCA LOXASPERSE base and mixed and encapsulated according to theprocedure of Example 1 are combined, mixed and encapsulated according tothe procedure of Example 1. Each capsule contains approximately 0.0.515g vancomycin hydrochloride and 0.2 g mupirocin.

Example 20 Preparation of a Dry Formulation of 20% Mupirocin

20 g mupirocin is combined with 12.92 g PCCA LOXASPERSE base and mixedand encapsulated according to the procedure of Example 1 The sodiumphosphate dibasic powder is ground prior to mixing with the rest of theingredients. Each capsule contains approximately 0.2 g mupirocin.

Example 21 Preparation of a Dry Formulation of 15% Colistimethate Sodium

15 g colistimethate sodium is combined with 27 g PCCA LOXASPERSE baseand mixed and encapsulated according to the procedure of Example 1 Eachcapsule contains approximately 0.15 g colistimethate sodium. Thecapsules should be stored under refrigeration.

What is claimed is:
 1. A dry formulation comprising one or more of thefollowing actives in combination with pharmaceutically acceptableexcipients or additives: a) at least one antibiotic; b) at least oneanti-inflammatory steroid; and c) at least one antifungal agent.
 2. Thedry formulation of claim 1, wherein all of actives (a) to (c) areincluded.
 3. The dry formulation of claim 1, wherein thepharmaceutically acceptable excipients or additives include a base foruse in pharmaceutical compounding and manufacturing of topicalpreparations.
 4. The dry formulation of claim 1, wherein the dryformulation does not contain an antihistamine.
 5. The dry formulation ofclaim 1, comprising a combination of the following actives selected fromthe group consisting of: 5% azithromycin, 1.5% fluticasone, and 1.5%fluconazole; 8% sulfamethoxazole, 5% trimethoprim, 1.5% fluticasone, and1.5% fluconazole; 12.8% levofloxacin hemihydrate, 1.5% fluticasone, and1.5% fluconazole; 1.5% fluticasone and 1.5% fluconazole; 1.5%fluticasone 12.8% levofloxacin hemihydrate, 10% mupirocin, 1.5%fluticasone, and 5% itraconazole; 12.8% levofloxacin hemihydrate, 1.5%fluticasone, and 5% itraconazole; 12.8% levofloxacin hemihydrate, 1.5%fluticasone, and 1% amphotericin B; 16% tobramycin, 1.5% fluticasone,and 5% itraconazole; 16% tobramycin, 1.5% fluticasone, and 1%amphotericin B; 10% mupirocin, 1.5% fluticasone, and 5% itraconazole;10% mupirocin, 1.5% fluticasone, and 1% amphotericin B; 5.15% vancomycinhydrochloride, 1.5% fluticasone, and 5% itraconazole; 5.15% vancomycinhydrochloride, 1.5% fluticasone, and 1% amphotericin B; 16% tobramycin,20% mupirocin; 1.5% fluticasone and 1% amphotericin B; and 1.5%fluticasone and 5% itraconazole.
 6. A method of preparing an orallyadministrable formulation comprising forming the dry formulation ofclaim 1, into an oral rinse or an oral solution.
 7. An orallyadministrable formulation obtained by the method of claim
 6. 8. A methodfor treating inflammatory, ulcerative and painful conditions of mucosalsurfaces of the upper alimentary canal of a mammal comprisingadministering to said patient the orally administrable formulation ofclaim
 7. 9. The method of claim 8, wherein the orally administrableformulation is an oral rinse and wherein the method comprises: (1)swishing the oral rinse formulation; and (2) expectorating the oralrinse formulation.
 10. The method of claim 8, wherein the orallyadministrable formulation is an oral solution and wherein the methodcomprises: (1) swishing the oral solution; and (2) swallowing the oralsolution.
 11. A method of preparing an intranasally administrableformulation comprising forming the dry formulation of claim 1 into anasal solution or suspension with a diluent suitable for intranasaldelivery of active ingredients.
 12. An intranasally administrableformulation obtained by the method of claim
 11. 13. A method fortreating inflammatory, ulcerative and painful conditions of therespiratory tract, respiratory airways or lungs of a mammal comprisingadministering to said mammal the intranasally administrable formulationof claim
 12. 14. The method of claim 12, wherein the intranasallyadministrable formulation is administered by a method selected from thegroup consisting of inhalation, spraying, liquid stream lavage,nebulizing, and nasal irrigation.
 15. A dry formulation comprising oneor more of the following actives in combination with pharmaceuticallyacceptable excipients or additives: a) at least one leukotriene receptorantagonist; b) at least one anti-inflammatory steroid; and c) at leastone non-sedative antihistamine.
 16. The dry formulation of claim 15comprising the following actives: 0.3% montelukast, 1.5% fluticasone,0.2% levocetirizine dihydrochloride or 5.15% vancomycin hydrochloride,20% mupirocin, wherein the pharmaceutically acceptable excipients oradditives include a base for use in pharmaceutical compounding andmanufacturing of topical preparations.
 17. A method of preparing aformulation for aural administration comprising forming the dryformulation of claim 15 into a solution or suspension with a diluentsuitable for otic delivery of active ingredients.
 18. A formulation foraural administration obtained by the method of claim
 17. 19. A methodfor treating inflammatory, ulcerative and painful conditions of the earof a mammal comprising administering to said mammal the formulation foraural administration of claim
 15. 20. The method of claim 19, whereinthe formulation for aural administration is administered by instillationof the solution or suspension into the ear canal.
 21. The method ofclaim 19, wherein the administering three times a day.
 22. The method ofclaim 19, wherein the condition is selected from the group consistingof: otitis externa, otitis media, otorrhea, acute mastoiditis,otosclerosis, otic pain, otic bleeding, otic inflammation, Lermoyez'ssyndrome, Meniere's disease, vestibular neuronitis, benign paroxysmalpositional vertigo, herpes zoster oticus, Ramsay Hunt's syndrome, viralneuronitis, ganglionitis, geniculate herpes, labyrinthitis, purulentlabyrinthitis, perilymph fistulas, presbycusis, drug-inducedototoxicity, acoustic neuromas, aerotitis media, infectious myringitis,bullous myringitis, squamous cell carcinoma, basal cell carcinoma,pre-cancerous otic conditions, nonchromaffin paragangliomas,chemodectomas, glomus jugulare tumors, glomus tympanicum tumors,perichondritis, aural eczematoid dermatitis, malignant external otitis,subperichondrial hematoma, ceruminomas, impacted cerumen, sebaceouscysts, osteomas, keloids, otalgia, tinnitus, vertigo, tympanic membraneinfection, tympanitis, otic furuncles, petrositis, conductive andsensorineural hearing loss, epidural abscess, lateral sinus thrombosis,subdural empyema, otitic hydrocephalus, Dandy's syndrome, bullousmyringitis, diffuse external otitis, foreign bodies, keratosis obturans,otic neoplasm, otomycosis, trauma, acute barotitis media, acuteeustachian tube obstruction, postsurgical otalgia, cholesteatoma,infections related to an otic surgical procedure.